Physician profile
John Christopher Hoitink
NPI 1861484750
$11,797.43
in general payments reported to CMS, 2019-2025
55 companies · $125 in 2025
The $125 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,803 · 2020: $1,798 · 2021: $2,758 · 2022: $2,933 · 2023: $2,360 · 2024: $19.98 · 2025: $125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,505.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,504.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,722.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $1,176.25 | 2019-2023 | |
| Abbvie INC. | $826.83 | 2021-2023 | |
| Lilly USA, LLC | $750.04 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $701.15 | 2019-2023 | Farxiga, Breztri |
| Amgen INC. | $671.87 | 2019-2023 | Repatha, Otezla, Prolia |
| Astellas Pharma US INC | $580.69 | 2019-2023 | Veozah, Myrbetriq |
| Pfizer INC. | $567.97 | 2019-2023 | |
| Amarin Pharma, INC. | $424.77 | 2019-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $326.44 | 2019-2023 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $279.20 | 2019-2023 | Steglatro, Belsomra |
| Nevro Corp. | $259.17 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $250.96 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $250.53 | 2019-2023 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $232.02 | 2019-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hoitink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.